COMPASS Pathways Inc.

NASDAQ: CMPS

Company Logo

Company Overview

COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. 

The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The team is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. 

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America.

The company is headquartered in London, UK, with offices in New York, USA.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$2.70

Diluted EPS (ttm)

Management Team

Mr. George Jay Goldsmith
Co-Founder, Chair of the Board & CEO

Mr. Lars Christian Wilde
Co-Founder, Pres & Chief Bus. Officer

Dr. Ekaterina Malievskaia M.D.
Co-Founder, Chief Innovation Officer & Director

Mr. Piers John Morgan
Chief Financial Officer

Mr. Nate Poulsen J.D.
Gen. Counsel & Chief Legal Officer

Mr. Stephen D. Schultz
Sr. VP of Investor Relations

Ms. Tracy Cheung
Chief Communications Officer

Mr. Marco Mohwinckel
Chief Commercial Officer

Mr. Trevor Mill
Chief Devel. Officer

Dr. Greg Ryslik Ph.D.
Sr. VP of Data Science, Machine Learning & Digital Health Research

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$1,250,555,542

Shares Outstanding
34,805,331

Shares Short (% of Float)
467,120 (0%)

Insider Ownership
5%